Abstract
The goal of this study was to examine the mediating role of psychological resilience in the relationship between fear of relapse and quality of life in a sample of patients with multiple sclerosis (PwMS). This cross-sectional study was developed online. A total of 240 PwMS were surveyed using the Multiple Sclerosis Quality of Life inventory, the Fear of Relapse Scale and the Connor-Davidson Resilience Scale. To perform the mediation analysis PROCESS macro was used. In our study, fear of relapse was a predictor of psychological resilience and quality of life, and psychological resilience was a predictor of quality of life. Finally, psychological resilience showed a mediating role in the relationship between fear of relapse and quality of life. Considering that resilience is a modifiable variable, the implementation of interventions aimed at enhancing resilience can have a favorable impact on the psychological well-being and quality of life of patients with multiple sclerosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethics committee of the Department of Psychology of the Universidad Central Marta Abreu de Las Villas. All procedures performed in this study were in accordance with the ethical standards of the 1964 Helsinki Declaration. Informed consent was obtained from all participants included in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Acknowledgement: First of all we want to express our gratitude to all the people with MS who participated in the study. We especially thank the coordinators and patients of the EMA (Esclerosis Múltiple Argentina) and ALCEM (Asociación de Lucha Contra la Esclerosis Múltiple) associations, especially Flavia Ferrandina and Fernanda Anelli. We also thank the patient associations of Mexico, Uruguay, Cuba and the Dominican Republic. Additionally we thank Rocio Seijas (Escleroamigos) and Fernando Champomier (Emstrongs) who from their projects supported our research from the beginning. Finally, we especially thank Nicolás Edgardo Costa, coordinator of the program «The game does not end» (ALCEM podcast series made by people living with MS).
(Yunier Broche-Pérez: (yunierbp{at}uclv.edu.cu, yunierbroche{at}gmail.com) (Zoylen Fernández-Fleitez: zfernandez{at}uclv.cu)
mauricio770927{at}gmail.com
lomr356{at}gmail.com
lazarovg{at}infomed.sld.cu
johana{at}ema.org.ar
Data Availability
All data produced in the present study are available upon reasonable request to the authors.